Could a simple drug combo heal jaw bone damage?
NCT ID NCT05795647
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of pentoxifylline and vitamin E can help heal jaw bone damage caused by certain osteoporosis or cancer drugs. The study will enroll 17 adults with stage 2 medication-related osteonecrosis of the jaw. Researchers will measure how many patients have less than 5 mm of exposed bone after 12 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pentoxifylline and tocopherol (vitamin E)
- What this could lead to
- If it works, this could offer a new treatment option for people with jaw bone damage caused by certain medications, potentially reducing pain and improving quality of life.
- What could go wrong
- This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The treatment may not work better than current options, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Limoges university hospital
RECRUITINGLimoges, 87042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.